The researchers said that they have demonstrated an approach that skirts a bottleneck and enables building pathology support systems from large datasets.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
The new partnership also gives clinical Dx analytics firm Prognos access to Datavant's pharma and biotech customers.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
The firm said that it will use the funding to support business activities to meet demand for its approach to clinical trial recruitment.
The companies anticipate providing services that combine Flagship’s biomarker development and Indivumed’s multiplex IHC assay development capabilities.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The spinout expects to launch its artificial intelligence- and biomarker-based monitoring tool in the third quarter of this year.